MINAPHARM
PHARMACEUTICALS
ميناقارم للأدوية

MINUTES OF THE MEETING OF THE BOARD OF DIRECTORS OF MINAPHARM PHARMACEUTICALS & CHEMICAL INDUSTRIES HELD ON4/5/2026

On, corresponding toat three pm, the Board of Directors of (Minapharm Pharmaceuticals & Chemical Industries), convened at the premises of the Company's factories at the Third Industrial Zone A2, Tenth of Ramadan City, Sharkia Governorate,

Under the chairmanship of Dr. Wafik Saad El-Bardissi, Chairman of the Board of Directors & Managing Director, in the presence of each of:

Dr. Amr Mohamed Sobhy Hamza Elshabrawishi	Vice-Chairman of the Board
Dr. Shahir Wafik Saad El-Bardissi	Managing Director
Dr. Anwar Nasr Mikhail	Member of the Board
Mr.mohamoud selim mohamoud	Member of the Board

To discuss the following agenda:

1- Ratification of the minutes of the Board of Directors on 27/11/2025
2- Ratification of the governance report on December 31, 2025
3- Ratification of the separate financial statements as at December 31, 2025
4- The approval of the profit distribution draft for the financial year ending as at December 31, 2025
5- Fixation of the date for convening the Company's Ordinary General Assembly for the financial year ending as at December 31, 2025
6- The authorization to have the minuets legalized
7- Works which may be revealed

Secretary

Board Chairman

<u>First Subject-Matter: Ratification of the minutes of the Board Meeting on December 9, 2025</u>
After the Board Members have perused the meeting minutes on27/11/2025, and as there are no remarks to make, the Board decided the following:

<u>Decision</u>
It has been decided to legalize the minutes of the Board Meeting held on.27/11/2025

<u>Second Subject-Matter: Ratification of the Stock Exchange Report</u>

The Board of Directors have had access to & approved the governance report for the year 2025, ratified by the Auditor.

<u>Decision</u>
The Board approved the governance report, ratified by the Auditor and submitted it before the General Assembly. for approval.

<u>Third Subject-Matter:</u>
The Board of Directors discussed the Company's financial statements for the financial year ending as at December 31, 2025, as follows:

The Company realized sales in the amount of million.3847.1 pounds during the financial year ending as at December 31, 2025, against million 3361.60 pounds for the financial year ending as at31/12/2024, with an increase in the amount of million485.50 pounds, at an increase percentage of 14.44 %. The cost of sales. amounted to million2621.30 pounds as at31/12/2025, at a percentage of68.13 %of sales.

The company realized a net profit of.57.4 million pounds at 31/12/2025, against million 162.80 pounds as at31/12/2024, at a Decrease 105.30 million pounds.

After discussing the items of the financial statements for the financial year ending as at December 31, 2025, the Board of Directors submitted its deep thanks and esteem to the Company's personnel for the efforts they have exerted. The Board decided the following:

<u>Decision:</u>
To approve the separate financial statements of the Company as at December 31, 2025 and to submit them before the General Assembly for ratification

Fourth Subject-Matter: The draft of profit distribution for the financial year ending as at December 31, 2025

The Board of Directors discussed the draft of profit distribution for the financial year ending as at December 31, 2025:

Net profit of the financial year ending as at December 31, 2025	EGP 57472127.00
Added: Retained profits as at December 31, 2024	EGP 1858413045.00
Total distributable profits as at December 31, 2025	EGP 1915885172.00
Distributed as follows:	
Legal reserve	
Shareholders dividend	EGP 29452350.00
Personnel dividend	EGP 30000000.00
Remuneration of the Board Members	EGP 3600000.00
Total distributions	EGP 63052350.00
Total retained profits	EGP 1852832822.00

Fifth Subject-Matter: Determination of the date for holding the General Assembly

The Board of Directors decided to fix the day2/6/2026on theusday of, corresponding to, at 3 pm, for convening the Company's General Assembly, at the premises of the Company's Factories in the Tenth of Ramadan City, in order to discuss the following subject-matters:

1- Ratification of the report of the Board of Directors and the governance report on the company's activity for the financial year ending as at December 31, 2025
2- Ratification of the auditor's report on the company's activity for the financial year ending as at December 31, 2025
3- Ratification of the Company's final accounts and separate financial statements for the financial year ending as at December 31, 2025
4- The approval to the profit distribution draft for the financial year ending as at December 31, 2025
5- Clearance of the Board Chairman, Managing Director & Board Members for the financial year ending as at December 31, 2025
6- Determination of the attendance allowance and transportation expenses of the Board Members for the financial year ending as at December 31, 2026

Office El-Bardissi Str., 2T Takseem Assmaa Fahmy, Heliopolis, Cairo, Egypt. T: (202) 24143170/1/2/3/4/5 - F: (202) 24143179
Factory Mina Str., 3rd Industrial Zone A2, 10th of Ramadan City, Egypt. T: (2015) 413115 - 412157 - F: (2015) 413109
www.minapharm.com

المكتب شارع البرديسى، ٢ط تقسيم اسماء فهمى، هليوبوليس،
القاهرة، مصر. ت : ٢٤١٤٣١٧٠/١/٢/٣/٤/٥(٢٠٢) - ف: ٢٤١٤٣١٧٩(٢٠٢)
المصنع شارع مينا، المنطقة الصناعية الثالثة A2، مدينة العاشر
من رمضان، مصر. ت: ٤١٣١١٥ - ٤١٢١٥٧(٢٠١٥) - ف: ٤١٣١٠٩(٢٠١٥)

7- Renewal of the appointment of the Auditors and fixation of their fees for the financial year ending as at December 31, 2026

8- Authorizing the Board of Directors to grant donations during the year 2026 within the limits decided under Law number 159 for the year 1981

9- Authorizing the Board of Directors to conclude commutative contracts during 2026

10- The authorization to have the minutes ratified

Sixth Subject-Matter: The authorization to have these minutes ratified

The Board of Directors agreed to authorize Messrs. Mohamed Mahmoud Abdelsalam, Mahmoud Mohsen Mahmoud, Ahmed Mohamed Abdelfattah or Mohamed Mahmoud Elbastawisi, either jointly or severally, to have the minutes ratified by the General Authority for Investment & Free Zones.

Seventh Subject-Matter: Issues which may be revealed

As there are no further issues to be discussed, the meeting was adjourned at four pm and the meeting chairman submitted his thanks and esteem to the attendees.

Secretary

Board Chairman & Managing Director

شركة مينا فارم للأدوية والصناعات الكيماوية
٢ط ش البرديسي من أسماء فهمي
خلف الرقابة الادارية - أرض الجولف

Acknowledgement

I, Wafik Saad El-Bardissi , Chairman of Board of Directors & Managing Director of Minapharm Pharmaceuticals & Chemical Industries, hereby acknowledge that I am legally liable for the soundness of the particulars, facts and procedures included in the minutes of the Board of Directors, held on,4/5/2026 towards third party, the shareholders and the General Authority for Investment & Free Zones. This acknowledgement is made in witness whereof.

I undertake to keep all documents supporting the happenings of the meeting at the Company's premises and I guarantee their conformity with the provisions of the Law, the Articles of Association and their amendments. I undertake to submit them on demand.

Chairman of the Board of Directors & Managing Director
Dr. Wafik El-Bardissi

شركة مينا فارم للأدوية والصناعات الكيماوية